133 related articles for article (PubMed ID: 10423661)
21. Trouble at the office.
Allison M
Nat Biotechnol; 2008 Sep; 26(9):967-9. PubMed ID: 18779797
[No Abstract] [Full Text] [Related]
22. Moment of reckoning.
Wadman M
Nature; 2007 Apr; 446(7138):844-5. PubMed ID: 17443154
[No Abstract] [Full Text] [Related]
23. Product safety and business interests: deja vu..
Rijswijk L
Ostomy Wound Manage; 2005 Feb; 51(2):8-9. PubMed ID: 15699549
[No Abstract] [Full Text] [Related]
24. They are from the government and they really are here to help you.
Woosley RL
J Clin Pharmacol; 2008 Feb; 48(2):142-3. PubMed ID: 18199889
[No Abstract] [Full Text] [Related]
25. Maine law requires drug companies to provide clinical trial data.
Appell D
J Natl Cancer Inst; 2005 Sep; 97(17):1246. PubMed ID: 16145043
[No Abstract] [Full Text] [Related]
26. Cautious welcome for FDA pharmacogenomics guidance.
Katsnelson A;
Nat Biotechnol; 2005 May; 23(5):510. PubMed ID: 15877053
[No Abstract] [Full Text] [Related]
27. Drug development research: the process.
Sataloff RT
Ear Nose Throat J; 2008 Aug; 87(8):420-2. PubMed ID: 18712686
[No Abstract] [Full Text] [Related]
28. Drugs tested for women.
Gershon D
Nature; 1992 Jan; 355(6358):287. PubMed ID: 1731234
[No Abstract] [Full Text] [Related]
29. Communicating with the FDA: the "third rail" of a new model for drug development.
Stanski DR; Orloff JJ
J Clin Pharmacol; 2008 Feb; 48(2):144-5. PubMed ID: 18199890
[No Abstract] [Full Text] [Related]
30. A critical tipping point.
Zuckerman MB
US News World Rep; 2002 Apr; 132(13):72. PubMed ID: 11993366
[No Abstract] [Full Text] [Related]
31. Disease models.
Gobburu J
Clin Adv Hematol Oncol; 2008 Apr; 6(4):241-2. PubMed ID: 18496490
[No Abstract] [Full Text] [Related]
32. Tricky FDA debate: should a risky drug be approved again?
Mathews AW; Westphal SP
Wall St J (East Ed); 2006 Feb; ():B1, B4. PubMed ID: 16528879
[No Abstract] [Full Text] [Related]
33. Pediatric study of medicines becomes mandatory.
Bonetta L
Nat Med; 2000 Oct; 6(10):1069. PubMed ID: 11017118
[No Abstract] [Full Text] [Related]
34. Interview with Gary L. Yingling, J.D.
Yingling GL
Qual Manag Health Care; 1999; 7(3):45-7. PubMed ID: 10537462
[No Abstract] [Full Text] [Related]
35. The challenge of regulating development and approval of drugs with pleiotropic action in cardiovascular disease.
Temple R
Am J Cardiol; 1998 Apr; 81(8A):5F-9F. PubMed ID: 9604896
[No Abstract] [Full Text] [Related]
36. FDA notifications. NRTI Emtriva receives FDA approval.
AIDS Alert; 2003 Oct; 18(10):131-2. PubMed ID: 14686301
[TBL] [Abstract][Full Text] [Related]
37. Earlier drug tests on people could be unsafe, critics warn.
Wadman M
Nat Med; 2006 Feb; 12(2):153. PubMed ID: 16462779
[No Abstract] [Full Text] [Related]
38. Clinical trial design issues in schizophrenic research.
Casey DE
J Clin Psychiatry; 2001; 62 Suppl 9():17-20; discussion 21-2. PubMed ID: 11379826
[TBL] [Abstract][Full Text] [Related]
39. No way to save a life: allowing terminally ill patients access to drugs that have not completed clinical trials is a dangerous move.
Moss RW
New Sci; 2006 Jun 3-9; 190(2554):21. PubMed ID: 16832956
[No Abstract] [Full Text] [Related]
40. Vision and will: the future of the FDA.
Epstein D
Oncologist; 2009 Apr; 14(4):317-9. PubMed ID: 19365098
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
